Get the Stockscreener App
6.85
0.74%
0.05
Pre-market:
5.78
-1.07
-15.62%
Protara Therapeutics Inc stock is traded at $6.85, with a volume of 654.93K.
It is up +0.74% in the last 24 hours and up +47.47% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$6.80
Open:
$6.69
24h Volume:
654.93K
Relative Volume:
1.10
Market Cap:
$264.32M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-2.4291
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-7.49%
1M Performance:
+47.47%
6M Performance:
+112.73%
1Y Performance:
+93.50%
1-Day Range:
$6.65
$7.05
1-Week Range:
$6.21
$7.54
52-Week Range:
$2.77
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
6.85 | 262.39M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadership2025 Retail Activity & Safe Entry Point Alerts - Newser
Protara Therapeutics prices $75 million public offering - Investing.com
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com UK
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Announces Pricing of $75 Million Public Offering - GlobeNewswire
Key Managers Announced for TARA Offering - GuruFocus
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara announces proposed public offering - MSN
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Announces Proposed Public Offering - GlobeNewswire
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - MarketScreener
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer - RTTNews
Protara Therapeutics reports positive results from bladder cancer study - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Jumps 14.6% in Pre-market Trading: After Positive Data Release - Stocks Telegraph
Protara Therapeutics (TARA) Reveals Promising Data from Phase 2 Bladder Cancer Trial - GuruFocus
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - marketscreener.com
Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growthTrade Entry Summary & Safe Capital Allocation Plans - Newser
Adversity is less terrifying than hope: Protara Therapeutics Inc (TARA) - Setenews
Will Protara Therapeutics Inc. (1KPA) stock sustain uptrend momentum2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Protara to host conference call on TARA-002 bladder cancer trial data - Investing.com Nigeria
Protara Therapeutics to Host Conference Call on December 3 to Discuss Interim Phase 2 Data for TARA-002 in Bladder Cancer - Quiver Quantitative
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Is Protara Therapeutics Inc. stock trading near support levelsJuly 2025 Sentiment & Stock Portfolio Risk Control - BỘ NỘI VỤ
Why Protara Therapeutics Inc. stock could outperform in 2025Earnings Miss & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
This Insider Bought 20000.0 Shares In Protara Therapeutics Inc (TARA) - fostersleader.com
HC Wainwright Has Positive Outlook for TARA Q4 Earnings - MarketBeat
HC Wainwright Has Positive Forecast for TARA Q4 Earnings - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Brokers Set Expectations for TARA Q2 Earnings - Defense World
Protara sees Chugai blue sky in LMs as phase II data strong - BioWorld MedTech
What analysts say about Protara Therapeutics Inc stockBullish Engulfing Patterns & Low Risk Trading Portfolio - earlytimes.in
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30% - Yahoo Finance
Revenue per share of Protara Therapeutics, Inc. – HAM:1KPA - TradingView
Will Protara Therapeutics Inc. (1KPA) stock maintain strong growthWeekly Volume Report & Target Return Focused Picks - newser.com
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):